{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T22:33:07Z","timestamp":1790289187023,"version":"4.1.0"},"reference-count":11,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,5]]},"DOI":"10.1097\/rlu.0b013e318286c148","type":"journal-article","created":{"date-parts":[[2013,3,22]],"date-time":"2013-03-22T21:32:22Z","timestamp":1363987942000},"page":"381-384","source":"Crossref","is-referenced-by-count":14,"title":["Distinguishing Pseudoprogression From Progression in High-Grade Gliomas"],"prefix":"10.1097","volume":"38","author":[{"given":"Matthew J.","family":"Oborski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles M.","family":"Laymon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank S.","family":"Lieberman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James M.","family":"Mountz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-17-20210204","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1200\/JCO.1990.8.7.1277","article-title":"Response criteria for phase II studies of supratentorial malignant glioma.","volume":"8","author":"Macdonald","year":"1990","journal-title":"J Clin Oncol"},{"key":"R2-17-20210204","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1200\/JCO.2009.26.3541","article-title":"Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group.","volume":"28","author":"Wen","year":"2010","journal-title":"J Clin Oncol"},{"key":"R3-17-20210204","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1038\/ncponc1204","article-title":"Response criteria for glioma.","volume":"5","author":"Sorensen","year":"2008","journal-title":"Nat Clin Pract Oncol"},{"key":"R4-17-20210204","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1212\/01.WNL.0000133398.11870.9A","article-title":"Immediate post-radiotherapy changes in malignant glioma can mimic tumor progression.","volume":"63","author":"de Wit","year":"2004","journal-title":"Neurology"},{"key":"R5-17-20210204","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1002\/cncr.23562","article-title":"Incidence of early pseudo-progression in a cohort of malignant glioma patients treated with chemoirradiation with temozolomide.","volume":"113","author":"Taal","year":"2008","journal-title":"Cancer"},{"key":"R6-17-20210204","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/S1470-2045(08)70125-6","article-title":"Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas.","volume":"9","author":"Brandsma","year":"2008","journal-title":"Lancet Oncol"},{"key":"R7-17-20210204","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.3174\/ajnr.A2397","article-title":"Pseudoprogression and pseudoresponse: imaging challenges in the assessment of posttreatment glioma.","volume":"32","author":"Hygino da Cruz","year":"2011","journal-title":"AJNR Am J Neuroradiol"},{"key":"R8-17-20210204","doi-asserted-by":"crossref","first-page":"2905","DOI":"10.1200\/JCO.2009.22.4998","article-title":"End point assessment in gliomas: novel treatments limit usefulness of classical Macdonalds Criteria.","volume":"27","author":"van den Bent","year":"2009","journal-title":"J Clin Oncol"},{"key":"R9-17-20210204","doi-asserted-by":"crossref","first-page":"e126","DOI":"10.3747\/co.v18i3.755","article-title":"Canadian recommendations for the treatment of recurrent or progressive glioblastoma multiforme.","volume":"18","author":"Easaw","year":"2011","journal-title":"Curr Oncol"},{"key":"R10-17-20210204","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/S0090-3019(03)00167-8","article-title":"Oligodendroglioma and anaplastic oligodendroglioma: clinical features, treatment, and prognosis.","volume":"60","author":"Engelhard","year":"2003","journal-title":"Surg Neurol"},{"key":"R11-17-20210204","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa043330","article-title":"Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.","volume":"352","author":"Stupp","year":"2005","journal-title":"N Engl J Med"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0b013e318286c148","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,24]],"date-time":"2021-05-24T19:29:40Z","timestamp":1621884580000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00003072-201305000-00017"}},"subtitle":["A Brief Review of Current Clinical Practice and Demonstration of the Potential Value of 18F-FDG PET"],"short-title":[],"issued":{"date-parts":[[2013,5]]},"references-count":11,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2013]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0b013e318286c148","relation":{},"ISSN":["0363-9762"],"issn-type":[{"value":"0363-9762","type":"print"}],"subject":[],"published":{"date-parts":[[2013,5]]}}}